Monitor for SEC effectiveness of the registration statement, which would allow the company to begin drawing on the ELOC. Any draw notice will signal immediate dilution and likely downward pressure on the stock price. Also watch for any updates on FDA regulatory pathway for nicotine strips or NIH grant decisions, as these are the only potential catalysts for a stock price recovery above $1.
Executive Summary
CTT Pharmaceutical Holdings filed Amendment No. 3 to its S-1 registration statement, registering 6,250,000 shares for resale by RH2 Equity Partners under an Equity Line of Credit (ELOC) agreement. The ELOC provides up to $10 million in potential funding, but the company is a development-stage pharmaceutical firm with no current revenue, a history of losses, and a going-concern qualification from its auditors. The stock trades on the OTCQB at $0.076 per share, and the filing updates the ELOC terms from the prior S-1/A filed in May 2026.
Key Facts
- 6,250,000 shares registered for resale by RH2 Equity Partners under an ELOC with a total commitment of up to $10,000,000
- Company has no revenue, net loss of $155,907 in FY2025 and $84,674 in Q1 2026, with an accumulated deficit of $7,636,137 as of March 31, 2026
- Auditors include a going-concern qualification; cash balance was only $7,089 as of March 31, 2026
- Purchase price under the ELOC is 85% of the lowest daily VWAP over the prior 10 business days, creating significant dilution risk
- Company plans to limit initial draws to $1 million unless stock price exceeds $1.00 per share
Financial Impact
Up to $10 million in gross proceeds possible from ELOC draws, but actual proceeds will be substantially less at current stock prices; at $0.076 per share, full issuance of 6,250,000 shares would yield only $475,000
Risk Factors
- Severe dilution from ELOC draws at deeply discounted prices (85% of VWAP)
- Going-concern risk with minimal cash and no revenue
- FDA approval uncertainty for nicotine strips; vitamin strips face competitive market entry
- Penny stock status and OTCQB listing limit liquidity and institutional interest
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001171520-26-000144 |
| Document: 0001171520-26-000144-index-headers.html | 0001171520-26-000144 |
| Document: 0001171520-26-000144-index.html | 0001171520-26-000144 |
| Document: 0001171520-26-000144.txt | 0001171520-26-000144 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | 8-K | $0.0566 | awaiting T+60 | — | $0.0566 (+0.00%) |
Oct 7, 2026 19d ago | 8-K | $0.0566 | awaiting T+60 | — | $0.0566 (−0.00%) |
Aug 12, 2026 10w ago | 8-K | $0.0660 | awaiting T+60 | — | $0.0566 (−14.24%) |
Jul 24, 2026 13w ago | S-1/A | $0.0660 $0.0589 | ▲ +10.76% | ▲ +14.31% | $0.0566 (+14.24%) |
Jun 29, 2026 17w ago | S-1/A | $0.0750 $0.0485 | ▲ +35.33% | ▲ +38.38% | $0.0566 (+24.53%) |
Jun 16, 2026 18w ago | S-1/A | $0.0800 $0.0518 | ▲ +35.25% | ▲ +38.66% | $0.0566 (+29.25%) |
May 29, 2026 21w ago | S-1/A | $0.0720 $0.0570 | ▲ +20.83% | ▲ +22.02% | $0.0566 (+21.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers